BC-819: Phase IIb started

BioCancell began an open-label, international Phase IIb trial to compare 8 and 12 mg intratumoral BC-819 plus 1,000 mg/m 2 IV gemcitabine vs. gemcitabine alone in about 100 patients with locally advan...